Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
MELVILLE, N.Y.--(BUSINESS WIRE)--Sept. 21, 2005--OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the...
MELVILLE, NY & SAN FRANCISCO--(BUSINESS WIRE)--Sept. 13, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc. (NYSE: DNA) announced today that the Oncologic Drug Advisory Committee...
PALO ALTO, Calif. and DEERFIELD, IL, August 10, 2005 – CV Therapeutics, Inc. (Nasdaq: CVTX) and Astellas Pharma US, Inc. announced today that the first of two pivotal Phase 3 studies of...
Read more about Regadenoson Meets Primary Endpoint in First Phase 3 Trial
MELVILLE, N.Y.--Aug. 8, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the Oncologic Drugs Advisory Committee (ODAC) panel will review at its September 13, 2005 meeting the...
MELVILLE, N.Y.--(BUSINESS WIRE)--July 13, 2005--OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) announced today that Health Canada has approved Tarceva® (erlotinib) for the treatment of patients with...
MELVILLE, N.Y.--(BUSINESS WIRE)--June 27, 2005--OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) announced today that its ex- U.S. partner for Tarceva® (erlotinib), Roche, received a positive opinion from...
MELVILLE, N.Y., Jun 02, 2005 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced the issuance of U.S. Patent No. 6,900,221 by the United States Patent and Trademark Office....
PRNewswire DEERFIELD, Ill. Astellas US LLC and Astellas Pharma US, Inc. ("Astellas") along with ITEM Development AB ("Item") announced today that they have filed a patent infringement lawsuit in...
Additional Milligram to Milligram Conversion Study Shows Equivalency of Prograf to MR Prograf SEATTLE, May 24, 2005 – Two studies presented today at the 6th American Transplant Congress (ATC)...
One Study of Early Steroid Withdrawal Reduced Cholesterol Levels and Decreased Onset of Post Transplant Diabetes SEATTLE, May 24, 2005 -- Early steroid withdrawal along with the use of tacrolimus...
ORLANDO, Fla., May 17, 2005 -- OSI Pharmaceuticals (Nasdaq: OSIP) First-Line, Monotherapy Non-Small Cell Lung Cancer Data Presented Symptom Response / Quality of Life Analysis from the...
ORLANDO, Fla., May 16, 2005 -- OSI Pharmaceuticals (Nasdaq:OSIP) provided an informational update summarizing highlights from presentations on the analysis of EGFR mutation and gene amplification...
Data Presented at Plenary Session at Annual ASCO Meeting ORLANDO, Fla., May 14, 2005 /PRNewswire-FirstCall via COMTEX/ -- Genentech, Inc. (NYSE: DNA) and OSI Pharmaceuticals (Nasdaq: OSIP) today...
MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 2, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc. (NYSE: DNA) announced today that OSI submitted a...
New Entity Ranks Astellas Among Top 20 Worldwide Pharmaceutical Companies Deerfield, Ill., April 1, 2005—Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. officially...
MELVILLE, N.Y.--(BUSINESS WIRE)--March 22, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the Swiss health authority, Swissmedic, has approved Tarceva™ (erlotinib) for the...
PRNewswire DEERFIELD, Ill. Fujisawa Healthcare, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the use of micafungin sodium, the antifungal product for...
PRNewswire DEERFIELD, Ill. and BASEL, Switzerland Fujisawa Healthcare, Inc. and Roche Pharmaceuticals today announced a partnership for the U.S. co-promotion of MYCAMINE™ (micafungin sodium)...
Read more about Fujisawa Healthcare, Inc. and Roche Announce Co-promotion of MYCAMINE™
First Astellas Product Launched in the United States PRNewswire DEERFIELD, Ill. Astellas Pharma US, Inc. announced today the launch and availability of their newest systemic anti-fungal agent...
Read more about Anti-Fungal Agent MYCAMINE™ Available to Physicians
Tarceva is the Only Epidermal Growth Factor Receptor (EGFR) Therapy to Show an Improvement in Survival in Pancreatic Cancer HOLLYWOOD, Fla.--(BUSINESS WIRE)--Jan. 27, 2005--OSI Pharmaceuticals,...
Follow U.S. news
